Overview

Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants

Status:
Not yet recruiting

Trial end date:
2023-01-26

Target enrollment:

Participant gender:

Summary

This is a phase 1, open-label, fixed-sequence, 2-period drug-drug interaction study to evaluate the pharmacokinetic interactions of itraconazole, rifampicin, midazolam, and SIM0417/ritonavir in healthy Chinese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Simcere Pharmaceutical Co., Ltd.

Treatments:

Itraconazole
Midazolam
Ritonavir